Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]: Feasibility Trial in Urban Pakistan
Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This project aims to adapt, implement, and evaluate PLA based intervention in urban Karachi, Pakistan for TIIDM prevention and control.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: t
View:
• Individuals aged 20 years and above.
• Participants residing in the randomized clusters of Karachi, Pakistan
• Individuals willing to participate in the study and provide consent.
• Both individuals with normoglycemia, intermediate hyperglycemia, and diabetes are encouraged to participate.
• Participants who can attend the scheduled meetings and interventions as per the study protocol.
Locations
Other Locations
Pakistan
Baqai Institute of Diabetology and Endocrinology (BIDE)
RECRUITING
Karachi
Contact Information
Primary
Abdul Basit, Director
abdulbasit@bide.edu.pk
922136688897
Backup
Rubia Zafar, TrialManager
rzafar@bide.edu.pk
Time Frame
Start Date: 2024-06-24
Estimated Completion Date: 2027-10
Participants
Target number of participants: 240
Treatments
Experimental: Intervention Group
Community mobilization will be done via male and female community groups using a PLA Cycle whereby groups themselves identify and priorities problems associated with diabetes and the risk of developing diabetes. Next this study will plan strategies to address the problems identified in the community, put these strategies into practice and, finally, evaluate the effectiveness of these strategies. Lay facilitators will convene the groups monthly over a period of 18 months, with one meeting per month.
No_intervention: Control Group
The Control Group will not receive the PLA (Participatory Learning and Action) intervention. However, they will still benefit from the study in several ways. Information about the trial and guidance on who to contact in case of hyperglycemia or intermediate hyperglycemia will be provided. The disease burden in the control area will be monitored, and findings will be included in national and international advocacy and dissemination efforts
Related Therapeutic Areas
Sponsors
Collaborators: University of York, Khyber Medical University Peshawar, HealthNet TPO, Aga Khan University Hospital, Pakistan, National Institute for Health Research, United Kingdom
Leads: Baqai Institute of Diabetology and Endocrinology